AMGEN Inc.

AMGN

$218.07

-11.8% last 12 months

Jim Simons Holding value: $245 Million Ken Griffin Holding value: $65.7 Million Ray Dalio Holding value: $35.8 Million Ken Fisher Holding value: $17.3 Million Joel Greenblatt Holding value: $3.99 Million Mario Gabelli Holding value: $1.21 Million Steven Cohen Holding value: $0 Ensemble Capital Holding value: $0 Jeremy Grantham Holding value: $0 Julian Robertson Holding value: $0 Tom Russo Holding value: $0 Daniel Loeb Holding value: $0 Chris Davis Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Donald Yacktman Holding value: $0 David Tepper Holding value: $0 Michael Burry Holding value: $0

Market Cap

$114 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$211.71 - $286.63

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

14.46x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$7.98 (3.73%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $114 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $145 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $7.98 (3.73%)
1 Year Return Profit or loss of share price change plus dividend yield. -8.1%
52-Week High Highest share price in the last 52 weeks. $286.63
52-Week Low Lowest share price in the last 52 weeks. $211.71
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 534 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 2.44 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 14.46
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 15.64
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $14.72
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.45
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 21.81
Enterprise Value to Revenue Enterprise value divided by revenue 5.52
Enterprise Value to EBIT Enterprise Value divided by EBIT 16.08
Total Debt to Enterprise Value Total debt divided by enterprise value 0.43
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 11.52

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $26.2 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $19.6 Billion
EBIT Earnings before tax and interest payments. $8.99 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $7.92 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 30.23%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +92.5%
Return on Equity Equity divided by market cap. 148.04%
Return on Assets Indicates a company's profitability in relation to its total assets. 8.92%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 12.06%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About AMGEN Inc.

CEO: Robert Bradway

Employees: 22,000

Industry: Biological Product (except Diagnostic) Manufacturing

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Similar stocks

Pfizer Inc.
Pfizer Inc.
GSK Plc - ADR
GSK Plc - ADR
Gilead Sciences, Inc.
Gilead Sciences, Inc.
Biogen Inc
Biogen Inc
Abbvie Inc
Abbvie Inc
Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc.
Johnson & Johnson
Johnson & Johnson
Illumina Inc
Illumina Inc
Lilly(Eli) & Co
Lilly(Eli) & Co

News

Disney, Amgen, First Republic, Psychedelics: How One CEO''s Universal Deal-Making Approach Shapes Industries

Disney, Amgen, First Republic, Psychedelics: How One CEO''s Universal Deal-Making Approach Shapes Industries

In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I''ve b...

Benzinga Benzinga, about 16 hours ago
The Biotech Buying Bonanza: Why The FTC''s Amgen Battle Won''t Chill The Spree

The Biotech Buying Bonanza: Why The FTC''s Amgen Battle Won''t Chill The Spree

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here''s where things stand.

Investor''s Business Daily Investor''s Business Daily, 4 days ago
Amgen Unusual Options Activity For June 01

Amgen Unusual Options Activity For June 01

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ: AMGN ). And retail traders should know. We noticed this today when the big ...

Benzinga Benzinga, 5 days ago
Is Amgen a healthcare stock worth considering? [Video]

Is Amgen a healthcare stock worth considering? [Video]

Amgen is a multinational biopharmaceutical company that specializes in the development and manufacturing of innovative therapies to treat serious illn

FXStreet FXStreet, 5 days ago
Never miss a trade
To improve your user experience we use cookies.